Long-Acting Lipoglycopeptides for the Treatment of Severe Infections
September 19th 2024Long-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.
Reassessing COVID-19 Treatments: Nirmatrelvir/Ritonavir and Molnupiravir Against New Variants
September 19th 2024Initially authorized based on promising trial data, recent analyses raise questions about the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new viral variants, particularly regarding mortality and hospitalization rates.
Discontinuation of Hepatitis C Treatment Early Did Not Preclude Sustained Virologic Response
September 15th 2024Overall, findings demonstrated a 78% treatment success rate among patients who prematurely discontinued direct-acting antivirals (DAA), and even seeing a 93% success rate among those who discontinued after week 4.
Assessing the Relationship Between C-diff Risk and Antibiotic Exposure
September 12th 2024C diff remains a major healthcare burden globally, with over 225,000 hospitalizations in the US alone. Over half of these cases had recent antibiotic exposure, underlining the significant relationship between antibiotic use and the risk of the healthcare-associated infection.